Abbott announced CE Marking for the ARCHITECT STAT High Sensitive Troponin-I Assay, which can measure very low levels of the protein, allowing doctors to evaluate whether or not patients are having a heart attack within two to four hours. This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests.
"The advantage of high sensitive troponin tests compared to current tests is that clinicians may now more precisely confirm or exclude a heart attack much sooner and with higher accuracy compared to contemporary tests," said Professor Stefan Blankenberg, director of cardiology at the University Heart Center of Hamburg, Germany. "This is important information for patient care because we can pursue treatment if needed or avoid invasive therapy and discharge a patient earlier."
The ARCHITECT STAT High Sensitive Troponin-I assay is a chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin I (cTnI) in human plasma and serum on the ARCHITECT i System with STAT protocol capability. The cTnI values are used as an aid in the diagnosis of myocardial infarction and to aid in the assessment of 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events consisting of myocardial infarction, revascularization, and cardiac death in patients who present with symptoms suggestive of acute coronary syndrome.
Abbott’s High Sensitive Troponin-I Assay also enables doctors to determine if patients are at risk to suffer from cardiovascular events 30 days and 90 days later.
The new assay runs on Abbott’s ARCHITECT family of analyzers and is available in CE marked and non-regulated countries, pending country registration.
In December 2012, Abbott announced a new testosterone test to measure the hormone at low levels to help diagnose related conditions in both men and women.